ProfileGDS5678 / 1441585_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 35% 33% 31% 31% 32% 43% 33% 31% 34% 33% 32% 37% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7789133
GSM967853U87-EV human glioblastoma xenograft - Control 22.7969535
GSM967854U87-EV human glioblastoma xenograft - Control 32.7501333
GSM967855U87-EV human glioblastoma xenograft - Control 42.6510231
GSM967856U87-EV human glioblastoma xenograft - Control 52.6538631
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8099832
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0604143
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7354233
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6721931
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7485734
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7435433
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7066832
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8428337
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9660342